Cyclophosphamide treatment induces profound suppression of ribosomal biogenesis, cytoplasmic translation, mitochondrial oxidative phosphorylation, and Wnt-associated regenerative programs in hair matrix cells, indicating a functional metabolic arrest preceding overt epithelial cell loss...Topical venlafaxine and its active metabolite desvenlafaxine preserved follicular architecture, suppressed apoptosis, and restored hair shaft elongation in both mouse CIA models and human hair follicle organ culture. At single-cell resolution, venlafaxine reversed epithelial translational shutdown, reactivated differentiation and Wnt signaling programs, and attenuated fibroinflammatory remodeling, thereby restoring paracrine niche signaling and matrix cell proliferation. Collectively, these findings redefine CIA as a disorder characterized by coordinated epithelial functional arrest and dermal inflammatory remodeling and identify venlafaxine as a potential pharmacological strategy to mitigate chemotherapy-associated hair loss.

24 days ago

Journal

IL6 (Interleukin 6) • FGF10 (Fibroblast Growth Factor 10) • SLIT2 (Slit Guidance Ligand 2) • FGF7 (Fibroblast Growth Factor 7)

cyclophosphamide

25d

RNA binding motif single-stranded interacting protein 1 drives renal fibrosis by stabilizing Annexin A8 mRNA to activate PI3K/AKT signaling. (PubMed, Int J Biol Macromol)

Pharmacological inhibition of RBMS1 with nortriptyline (NTP) significantly attenuated renal fibrosis in unilateral ureteral obstruction (UUO) mice. These results reveal an RBMS1/ANXA8/PI3K/AKT regulatory axis in renal fibrosis, highlighting RBMS1 as a potential therapeutic target.

25 days ago

Journal

TGFB1 (Transforming Growth Factor Beta 1) • RRM2 (Ribonucleotide Reductase Regulatory Subunit M2) • RBMS1 (RNA Binding Motif Single Stranded Interacting Protein 1)

27d

Identifying and Treating Depression in the Orthopaedic Trauma Population (clinicaltrials.gov)

P4, N=100, Recruiting, Wake Forest University Health Sciences | Trial completion date: May 2026 --> May 2027 | Trial primary completion date: May 2026 --> May 2027

27 days ago

Trial completion date • Trial primary completion date

fluoxetine

A Study of CSTI-500 in Patients With Prader-Willi Syndrome (clinicaltrials.gov)

P2, N=12, Recruiting, ConSynance Therapeutics | Not yet recruiting --> Recruiting

1 month ago

Enrollment open

A Trial of Centanafadine Long-term Safety in Children and Adolescents With Attention-deficit/Hyperactivity Disorder. (clinicaltrials.gov)

P3, N=680, Completed, Otsuka Pharmaceutical Development & Commercialization, Inc. | Active, not recruiting --> Completed

1 month ago

Trial completion

P3b Short-term Study of CTN in Patients With ADHD and Comorbid Anxiety (clinicaltrials.gov)

P3, N=315, Completed, Otsuka Pharmaceutical Development & Commercialization, Inc. | Active, not recruiting --> Completed

1 month ago

Trial completion

A Trial to Assess How Centanafadine Interacts With Stimulants in the Body (clinicaltrials.gov)

P1, N=40, Completed, Otsuka Pharmaceutical Development & Commercialization, Inc. | Recruiting --> Completed

1 month ago

Trial completion

2ms

MRP-HAND: Multiprofen-CC to Reduce Pain in Hand Arthritis (clinicaltrials.gov)

P3, N=42, Recruiting, St. Joseph's Healthcare Hamilton | Not yet recruiting --> Recruiting

2 months ago

Enrollment open

amitriptyline